ONEX: Closes RMB 100M-Level First Round Led by IDG Capital
NewTimeSpace News: On 18 November 2026, OneX Intelligence (Shanghai OneX Intelligence Technology Co., Ltd., unlisted) announced a first round of several hundred million yuan, led by IDG Capital with China Creation Ventures (CCV), Yunbai Capital, Jiaoda Hanyuan Assets and Yunqi Partners following; Palm Capital acted as financial adviser. The exact amount and post-money valuation were not disclosed. Proceeds will mainly fund research on a foundation model for life science, a wet-lab platform and industrial collaboration validation. Based at the Shanghai Jiao Tong University research institute in Xuhui district, the company was initiated by Professor Wang Yanfeng of the School of Artificial Intelligence; Zhang Ya and Xie Weidi are co-founders, with Xie serving as CEO and chief scientist.
OneX Intelligence works on a Foundation Model for Life Science, building a unified cross-species, cross-modal and cross-scale model based on the central dogma that links DNA, RNA, proteins, cells, tissues and disease phenotypes, to understand how life states evolve and predict the effects of genetic, drug and environmental interventions. It builds a life-simulation model centred on virtual cells and tests predictions through real experiments.
The team has validated related capabilities in several studies: the rare-disease evidence-reasoning system DeepRare was published in Nature, the tumour pathology multi-modal model KEEP in Cancer Cell, and the cell-perturbation prediction model MAP in Nature Machine Intelligence; the cell-phenotype and bioactivity model OpenPheno has been accepted by Nature Chemical Biology. Xie received the Young Scientist Award at the inaugural World Laureates Awards ceremony on 31 October 2026, one of six recipients worldwide. Co-founder Zhang Ya is vice dean and distinguished professor at Shanghai Jiao Tong University's School of Artificial Intelligence.
The company plans a wet-lab platform that folds model development, biological observation and experimental validation into one loop, and intends to offer callable capabilities to researchers, hospitals and drug companies through a model-as-a-service model. It says it is in talks with pharmaceutical companies and contract development and manufacturing organisations. Zhou Wei, founding managing partner of CCV, cited the team's model-experiment-data loop; representatives of Jiaoda Hanyuan Assets and Yunqi Partners also gave reasons for investing.